Quarterly ResultAug 12, 2026, 06:07 AM
Annexon GBS BLA Q4 2026; GA Program Expands; $200M Credit Facility
AI Summary
Annexon reported Q2 2026 financial results, highlighted significant clinical progress, and secured a $200 million credit facility. The company expects to submit a Biologics License Application (BLA) for tanruprubart in Guillain-Barré syndrome (GBS) in Q4 2026, following positive clinical outcomes. The Phase 3 program for vonaprument in geographic atrophy (GA) was expanded with a dual primary endpoint strategy, with Month 15 data expected in Q4 2026. The new credit facility extends the anticipated cash runway into 2028.
Key Highlights
- Tanruprubart BLA submission for GBS expected in Q4 2026.
- Vonaprument Phase 3 GA program expanded with Month 15/24 dual primary endpoint.
- Vonaprument Month 15 primary endpoint data on track for Q4 2026.
- ANX1502 POC data for autoimmune disease anticipated in Fall 2026.
- Secured $200 million credit facility, with $50 million drawn at closing.
- Anticipated cash runway extended into 2028.
- Q2 2026 net loss attributable to common stockholders was $55.3 million.
- Cash, cash equivalents, and short-term investments totaled $209.2 million as of June 30, 2026.
Price Impact
More from ANNX